Want to see HK:0719 full AI Analyst Report?
0719 Stock Chart & Stats
HK$6.67
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$6.67
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$5.18 - HK$7.64
Previous CloseN/A
Volume2.84M
Average Volume (3M)346.04K
Market Cap
HK$8.92B
Enterprise ValueHK$4.67K
Total Cash (Recent Filing)HK$1.51B
Total Debt (Recent Filing)HK$1.96B
Price to Earnings (P/E)47.4
Beta0.70
Next Earnings
Oct 23, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend Yield2.73%
Share Statistics
EPS (TTM)0.31
Shares Outstanding195,000,000
10 Day Avg. Volume343,280
30 Day Avg. Volume346,040
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)0.78
Price to Sales (P/S)0.47
P/FCF Ratio9.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.81
Revenue Forecast (FY)HK$9.22B
Bulls Say, Bears Say
Bulls Say
Diversified Pharmaceutical ManufacturingThe company spans APIs, finished medicines, and chemical intermediates, giving it multiple routes to pharmaceutical demand. This vertical breadth can support production flexibility, broaden customer applications, and reduce reliance on a single product category over the next several quarters.
Moderate LeverageModerate leverage provides a serviceable financial base and preserves more flexibility than a highly indebted structure. Although debt-to-equity increased in the latest period, the stated range suggests the company retains capacity to fund operations and manage obligations.
Positive Improving Free Cash FlowPositive and improving free cash flow supports the company’s ability to finance operations, maintain assets, and pursue priorities with internally generated funds. The latest 19.5% increase is constructive, even though the broader cash-conversion record remains uneven.
Bears Say
TTM Revenue DeclineThe latest revenue contraction interrupts the company’s earlier growth trajectory and signals weaker demand or pricing conditions. Sustained top-line pressure would reduce operating leverage, constrain reinvestment, and make recovery in earnings more dependent on cost control.
Material Margin CompressionSharp declines in gross and net margins materially weaken earnings power and reduce the buffer available to absorb cost or pricing pressure. With net margin near 2.5%, relatively small changes in operations could continue to produce significant swings in profitability.
Inconsistent Cash ConversionPositive free cash flow is offset by weak and inconsistent conversion of operating profit into cash. This pattern may tie up resources in working capital or timing differences, limiting the reliability of internally funded investment and shareholder returns over time.
Shandong Xinhua Pharmaceutical Company Limited Class H News
0719 FAQ
What was Shandong Xinhua Pharmaceutical Company Limited Class H’s price range in the past 12 months?
Shandong Xinhua Pharmaceutical Company Limited Class H lowest stock price was HK$5.18 and its highest was HK$7.64 in the past 12 months.
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap?
Shandong Xinhua Pharmaceutical Company Limited Class H’s market cap is HK$8.92B.
When is Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date?
Shandong Xinhua Pharmaceutical Company Limited Class H’s upcoming earnings report date is Oct 23, 2026 which is in 30 days.
How were Shandong Xinhua Pharmaceutical Company Limited Class H’s earnings last quarter?
Shandong Xinhua Pharmaceutical Company Limited Class H released its earnings results on Aug 25, 2026. The company reported HK$0.105 earnings per share for the quarter, missing the consensus estimate of HK$0.199 by -HK$0.094.
Is Shandong Xinhua Pharmaceutical Company Limited Class H overvalued?
According to Wall Street analysts Shandong Xinhua Pharmaceutical Company Limited Class H’s price is currently Overvalued.
Does Shandong Xinhua Pharmaceutical Company Limited Class H pay dividends?
Shandong Xinhua Pharmaceutical Company Limited Class H pays a Annually dividend of HK$0.172 which represents an annual dividend yield of 2.73%. See more information on Shandong Xinhua Pharmaceutical Company Limited Class H dividends here
What is Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate?
Shandong Xinhua Pharmaceutical Company Limited Class H’s EPS estimate is 0.14.
How many shares outstanding does Shandong Xinhua Pharmaceutical Company Limited Class H have?
Shandong Xinhua Pharmaceutical Company Limited Class H has 195,000,000 shares outstanding.
What happened to Shandong Xinhua Pharmaceutical Company Limited Class H’s price movement after its last earnings report?
Shandong Xinhua Pharmaceutical Company Limited Class H reported an EPS of HK$0.105 in its last earnings report, missing expectations of HK$0.199. Following the earnings report the stock price went up 0.523%.
Which hedge fund is a major shareholder of Shandong Xinhua Pharmaceutical Company Limited Class H?
Currently, no hedge funds are holding shares in HK:0719
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shandong Xinhua Pharmaceutical Company Limited Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.16%
12-Months-Change
Fundamentals
Return on Equity
2.73%
Trailing 12-Months
Asset Growth
3.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. It also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, the company offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate leasing, and housing leasing activities; certification and import and export business; electrical equipment engineering; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. Shandong Xinhua Pharmaceutical Company Limited was founded in 1943 and is based in Zibo, the People's Republic of China.
Shandong Xinhua Pharmaceutical Company Limited Class H (0719) Earnings & Revenues
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Sihuan Pharmaceutical Holdings Group
―
China Resources Pharmaceutical Group Ltd.
―
Consun Pharmaceutical Group Ltd.
―